Altogether, CPH:SA‐based IL‐1α‐MPs demonstrated promising sustained systemic release kinetics accompanied by minimal weight loss, cytokine storm and hypotension and retention of anti‐tumor activity. The gene discussed is IL1A; the disease is neoplasm.